Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - vardenafil hydrochloride 11,85 mg - eq. vardenafil 10 mg - film-coated tablet - 10 mg - vardenafil hydrochloride 11.85 mg - vardenafil

Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - vardenafil hydrochloride 5,926 mg - eq. vardenafil 5 mg - film-coated tablet - 5 mg - vardenafil hydrochloride 5.926 mg - vardenafil

Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - vardenafil hydrochloride 11,853 mg - eq. vardenafil 10 mg - film-coated tablet - 10 mg - vardenafil hydrochloride 11.853 mg - vardenafil

Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - vardenafil hydrochloride 23,705 mg - eq. vardenafil 20 mg - film-coated tablet - 20 mg - vardenafil hydrochloride 23.705 mg - vardenafil

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - vardenafil hydrochloride trihydrate - oral tablet - 20mg

USA - engelsk - NLM (National Library of Medicine)

macleods pharmaceuticals limited - vardenafil hydrochloride trihydrate (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil orally disintegrating tablet is indicated for the treatment of erectile dysfunction. administration of vardenafil orally disintegrating tablet with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including vardenafil orally disintegrating tablet, may potentiate the hypotensive effects of nitrates. a suitable time interval following vardenafil orally disintegrating tablet dosing for the safe administration of nitrates or nitric oxide donors has not been determined. do not use vardenafil orally disintegrating tablet in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including vardenafil orally disintegrating tablet may potentiate the hypotensive effects of gc stimulators. risk summary vardenafil orally disintegrating tablet is not indicated for use in females. there are

USA - engelsk - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - vardenafil hydrochloride (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride tablets are indicated for the treatment of erectile dysfunction. administration of vardenafil hydrochloride tablets with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including vardenafil hydrochloride tablets, may potentiate the hypotensive effects of nitrates. a suitable time interval following dosing of vardenafil hydrochloride tablets for the safe administration of nitrates or nitric oxide donors has not been determined. do not use vardenafil hydrochloride tablets in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including vardenafil hydrochloride tablets may potentiate the hypotensive effects of gc stimulators. risk summary vardenafil hydrochloride is not indicated for use in females. there are no data with the use of vardenafil hydrochloride in p

USA - engelsk - NLM (National Library of Medicine)

alembic pharmaceuticals limited - vardenafil hydrochloride (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride tablets are indicated for the treatment of erectile dysfunction. administration of vardenafil hydrochloride tablets with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including vardenafil hydrochloride tablets, may potentiate the hypotensive effects of nitrates. a suitable time interval following dosing of vardenafil hydrochloride tablets for the safe administration of nitrates or nitric oxide donors has not been determined. do not use vardenafil hydrochloride tablets in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including vardenafil hydrochloride tablets may potentiate the hypotensive effects of gc stimulators. pregnancy category b vardenafil hydrochloride is not indicated for use in women. there are no studies of vardenafil hydrochloride use in p

USA - engelsk - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - vardenafil hydrochloride trihydrate (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride tablets are indicated for the treatment of erectile dysfunction. administration of vardenafil with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including vardenafil, may potentiate the hypotensive effects of nitrates. a suitable time interval following dosing of vardenafil for the safe administration of nitrates or nitric oxide donors has not been determined.  do not use vardenafil in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including vardenafil may potentiate the hypotensive effects of gc stimulators. pregnancy category b vardenafil is not indicated for use in women. there are no studies of vardenafil use in pregnant women. no evidence of specific potential for teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits that

USA - engelsk - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - vardenafil hydrochloride (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride tablets are indicated for the treatment of erectile dysfunction. administration of vardenafil hydrochloride tablets with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including vardenafil hydrochloride tablets, may potentiate the hypotensive effects of nitrates. a suitable time interval following dosing of vardenafil hydrochloride tablets for the safe administration of nitrates or nitric oxide donors has not been determined. do not use vardenafil hydrochloride tablets in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including vardenafil hydrochloride tablets may potentiate the hypotensive effects of gc stimulators. pregnancy category b vardenafil hydrochloride tablets are not indicated for use in women.